multicentre

Related by string. Multicentre * * multicentre randomized double . multicentre study . multicentre randomized . randomized multicentre . multicentre randomized controlled . multicentre prospective . blind multicentre . Canadian Multicentre Osteoporosis . prospective multicentre . multicentre phase *

Related by context. All words. (Click for frequent words.) 81 multicenter 80 randomized multicenter 78 multicenter randomized 78 multicentre randomized 76 Phase III randomized 76 prospective multicenter 75 prospective randomized 75 randomized controlled 75 placebo controlled randomized 75 blind randomized 75 placebo controlled 74 randomized placebo controlled 74 multicenter prospective 74 multicenter randomized placebo controlled 74 prospective randomized controlled 73 prospective observational 73 multicenter randomized double 72 placebo controlled Phase III 72 randomized Phase III 72 multicentre randomized double 72 prospective randomized multicenter 72 multicenter randomized controlled 72 multicentre study 71 randomized 71 randomized clinical 71 Multicenter 71 Phase IIIb 71 randomized double 71 nonrandomized 70 controlled multicenter 70 blind randomized placebo 70 randomized multicentre 70 double blinded randomized 70 multicenter Phase II 70 multicenter study 70 TMC# C# 69 randomized multicenter trial 69 multicentre prospective 69 label multicenter 69 multicenter randomized clinical 69 multicenter clinical 68 Randomised 68 prospective randomized placebo 68 blind multicenter 68 prospective nonrandomized 68 randomized controlled clinical 68 blind randomized controlled 68 phase IIIb 68 placebo controlled clinical 68 multicenter placebo controlled 68 blinded randomized 67 masked placebo controlled 67 RE LY ® 67 multicenter multinational 67 randomized controlled trial 67 multicenter phase 67 multicentre randomized controlled 67 double blind placebo 67 double blinded placebo 67 Sorafenib HCC Assessment 67 placebo controlled Phase 67 AIR CF3 67 Phase IIIb study 66 prospective multicentre 66 NICE SUGAR 66 ADVANCE PD 66 randomized crossover 66 dose escalation Phase 66 randomized controlled Phase 66 blinded placebo controlled 66 EURIDIS 66 prospective multicenter randomized 66 randomized blinded placebo 66 multicenter Phase III 66 prospective cohort 66 RE LY 66 REALITY Trial 66 TG MV 65 randomized blinded 65 ONTARGET 65 dose escalation clinical 65 ECASS 65 blind placebo controlled 65 PRECiSE 65 Randomized controlled 65 landmark ATHENA 65 Randomized 65 dose escalation trial 65 placebo controlled studies 65 Phase #/#a 65 LUX Lung 64 ascending dose 64 Phase 1b clinical 64 ASTEROID 64 observational study 64 dose dose escalation 64 randomized controlled multicenter 64 NO# [002] 64 Randomized Evaluation 64 active comparator 64 trials RCTs 64 BCIRG 64 randomized controlled clinical trials 64 CLL8 64 phase Ib 64 subanalysis 64 phase IIa 64 dose escalation 64 Stenting Trial CREST 64 dose escalation study 64 EchoCRT 63 HCV SPRINT 63 substudy 63 ROCKET AF 63 Multicentre 63 blinded randomized placebo controlled 63 ExTRACT TIMI 63 label dose escalation 63 EORTC 63 RIO Lipids 63 placebo controlled dose escalation 63 randomized Phase IIb 63 BOLDER II 63 Phase Ib clinical 63 blind placebo 63 multicenter Phase 63 retrospective cohort study 63 DAPT Study 63 phase IIb clinical 63 retrospective observational study 63 BRIM2 63 Phase III multicenter 63 AIR CF2 63 Randomized Study 62 BRIM3 62 NSABP B 62 label dose titration 62 Phase 2b study 62 Prospective Randomized 62 placebo controlled trials 62 retrospective cohort 62 phase IIa clinical 62 Phase IIIb clinical 62 Carotid Revascularization Endarterectomy vs. 62 CARE HF 62 COPERNICUS 62 EVEREST II 62 multicentric 62 Phase III placebo controlled 62 Clinical Antipsychotic Trials 62 Thrombolysis 62 TAXUS ATLAS 62 OLYMPIA registry 61 cluster randomized controlled 61 phase IIb 61 Phase III randomized controlled 61 Phase IIb III 61 Phase Ib II 61 STRIDE PD 61 ASCEND HF 61 controlled dose escalation 61 label multicenter Phase 61 randomized placebo 61 Phase Ib 61 randomized Phase 61 TRITON TIMI 61 blinded randomized controlled 61 CIMZIA TM certolizumab pegol 61 thorough QT 61 DAPT 61 ENDEAVOR IV 61 prospectively randomized 61 pivotal bioequivalence 61 multicenter trials 61 PFO migraine 61 SORT OUT III 61 randomized trials 61 AIR CF1 61 Edge STudy 61 longitudinal cohort study 61 Intervention Trial 60 sequential dose escalation 60 noninferiority 60 non inferiority 60 prospective multicenter study 60 BR.# 60 treatment naive genotype 60 Phase 1b trial 60 Phase 1b 60 Betaferon ® 60 controlled multicenter Phase 60 COMFORT II 60 Placebo controlled 60 Phase III VISTA 60 Val HeFT 60 Cardiac Allograft Rejection 60 NCT# ClinicalTrials.gov 60 STICH trial 60 CALGB 60 VADT 60 AIM HIGH 60 Initiated Phase 60 recurrent malignant glioma 60 pharmacokinetic PK 60 blind randomized multicenter 60 Phase 2b trial 60 Phase 2b kidney transplant 60 confirmatory clinical 60 PRoFESS 60 Prostate Lung Colorectal 60 CHAMPION PCI 60 prospective observational cohort 60 pharmacokinetics PK 60 BARI 2D 60 Radiation Therapy Oncology 60 RoACTEMRA 60 Myocardial Infarction Study 60 randomized clinical trials 60 label multicenter randomized 60 pharmacokinetic PK study 59 registrational Phase 59 viral kinetic 59 confirmatory Phase III 59 ABCSG 59 clinical trial 59 Alpha Tocopherol Beta Carotene 59 prospectively defined 59 Phase 1a 59 CAMMS# 59 MEND CABG 59 oral deforolimus 59 placebo controlled multicenter 59 MADIT II 59 Ovarian Cancer Screening 59 EVA 3S 59 TAXUS V 59 EINSTEIN DVT 59 ABSORB trial 59 APTIVUS 59 multinational multicenter randomized 59 multicentre phase 59 Intervention Effectiveness CATIE 59 CLARITY TIMI 59 ATTRACT 59 PREVAIL 59 Multicenter Study 59 SWOG 59 landmark ATHENA trial 59 subgroup analyzes 59 Phase III pivotal 59 PLCO 59 observational cohort 59 RECORD1 59 ISAR TEST 59 designated HVTN 59 relapsing remitting MS RRMS 59 e HEALING 59 XIENCE V demonstrated 59 GOUT 59 LEXIVA r 59 HYVET 59 HCV RESPOND 2 59 unblinded 59 Prospective Randomized Trial 59 SYNTAX 58 ABSORB clinical 58 observational cohort study 58 PRECISE 58 relapsed APL 58 comparing XIENCE V 58 Phase 2a clinical 58 Ranolazine 58 phase Ib clinical 58 Intervention Effectiveness 58 GISSI HF 58 HORIZONS AMI trial 58 AIR2 Trial 58 unfractionated heparin UFH 58 Phase #b/#a 58 Phase 2b clinical 58 dose titration 58 Phase Ia 58 Phase 1a clinical 58 APPRAISE 58 LITHE 58 Prostate AdenoCarcinoma Treatment 58 Phase 2b randomized 58 #mg/day [001] 58 dabigatran etexilate 58 sunitinib malate 58 TAXUS IV 58 oral rivaroxaban 58 NSABP 58 clinical pharmacology studies 58 Trandolapril 58 ACTIVE W 58 Lodotra TM 58 MIVI III 58 randomized controlled trials 58 ritonavir boosted 58 Acute Myocardial Infarction 58 Acute Ischemic Stroke 58 CUSTOM II 58 Acute Decompensated Heart Failure 58 number NCT# ClinicalTrials.gov 58 RE LY trial 58 Left Ventricular Dysfunction 58 Multiple Ascending Dose 58 Pivotal Trial 58 EDEMA3 58 Intervention Trial GAIT 58 factorial design 58 rosuvastatin 58 Randomized Phase 58 pain palliation 58 pivotal Phase III 58 meta analysis 58 multicenter randomized Phase 58 VITAL Trial 58 phase IIb study 58 ENDEAVOR 58 single ascending dose 58 riociguat 58 RAVEL 58 evaluating REVLIMID 58 FREEDOMS 57 Phase III clinical 57 symptomatic BPH 57 CALGB # [002] 57 Phase Ib IIa 57 registrational 57 Amrubicin 57 ongoing Phase 1b 57 Phase IIb clinical 57 IMPROVE HF 57 Phase IIb trial 57 relapsing multiple sclerosis 57 multicenter randomized Phase III 57 Phase III 57 Chronic Heart Failure 57 Group RTOG 57 Screening Trial 57 Meta analyzes 57 rALLy clinical trial 57 neoadjuvant 57 RezularTM 57 Phase 2a trial 57 Long Lesion 57 anti arrhythmic drug 57 Feasibility Trial 57 ORMD 57 PRE SURGE 57 icatibant 57 dosage regimens 57 PRIMO CABG 57 prucalopride 57 metastatic HRPC 57 CYPHER Stent 57 ALLEGRO 57 MOTIVATE 57 cinacalcet 57 treatment naïve genotype 57 STENT 57 fosbretabulin 57 interferon beta 1b 57 Phase III psoriasis 57 phase III ACCLAIM 57 mg administered orally 57 pharmacodynamics PD 57 ascending dose study 57 everolimus eluting stent 57 AVADO 57 Endeavor Resolute DES 57 Cholesterol Levels SPARCL 57 BOLDER 57 Endovascular Valve Edge 57 AVERROES 57 UKPDS 57 XIENCE V Stent System 57 RADIANT 57 ADONIS 57 Phase Ib IIa clinical 57 Phase IIa trial 57 FAME Study 57 teriflunomide 57 RG# ITMN 57 Angiox R 57 HPTN 57 Myocardial Infarction 57 MADIT 57 Spine Patient Outcomes 57 TAXUS VI 57 TRANSCEND 57 EmbraceAC 57 ISAR REACT 57 blind multicentre 57 NOXAFIL Oral Suspension 57 randomized Phase 2b 56 ENESTnd 56 patients undergoing percutaneous 56 nab paclitaxel 56 Sequenced Treatment Alternatives 56 Gynecologic Oncology Group 56 RRMS patients 56 CURRENT OASIS 7 56 CLARITY study 56 MIST II 56 randomized #:#:# 56 ConclusionThis 56 darunavir r 56 GetGoal Phase III 56 TROPIC 56 subcutaneous methylnaltrexone 56 Phase III Psoriasis 56 MIRCERA 56 desvenlafaxine succinate 56 #mg QD [002] 56 Phase IIa 56 ACCOMPLISH 56 CATIE AD 56 REVIVE 56 Aggressive Reduction 56 ENGAGE AF TIMI 56 pharmacodynamic effects 56 ENDEAVOR clinical 56 prospective longitudinal 56 APEX PD 56 ZACTIMA 56 Multi Ethnic Study 56 irbesartan 56 Phase IIb 56 TRANSFORMS 56 randomized #:# 56 APRICOT 56 Phase IIa clinical 56 rFVIIa 56 #:# randomization 56 ADMIRE HF 56 ERSPC 56 Diabetes Interventions 56 safety tolerability pharmacokinetics 56 PreCISe 56 ARDIS 56 LUMINATE 56 ascending doses 56 SIMPADICO 56 IFN alfa 56 liver transplant recipients 56 Tocilizumab 56 CUSTOM III 56 biliary tract cancer 56 RSD# oral 56 dose escalation phase 56 RESOLUTE 56 AVOREN 56 SPIRIT IV 56 glatiramer acetate 56 paclitaxel poliglumex 56 pivotal Phase 56 PRESEPT 56 ADAGIO 56 RESOLUTE clinical 56 chemoradiotherapy 56 Phase 2b 56 Observational Study 56 Phase Ib study 56 Scandinavian Cardiac Outcomes 56 ARCOXIA 56 SPIRIT III 56 doxorubicin docetaxel 56 PERSEUS 56 Raloxifene Evaluation MORE 56 phase IIb trial 56 dose regimens 56 Aggressive Drug Evaluation 56 Phase III Clinical Trial 56 NATRECOR ® 56 acute coronary syndromes ACS 56 By JENNIFER LEARN 56 Randomized Phase II 56 placebo controlled clinical trials 56 IIa clinical 56 Polyp Prevention Trial 55 post hoc 55 SANTE 55 Val MARC 55 HORIZONS AMI 55 null responder HCV 55 noninferior 55 Protelos 55 Trial ASCOT 55 NEVO RES 55 Phase III randomized placebo 55 ENDEAVOR II 55 eptifibatide 55 Randomized Double Blind Placebo 55 relapsed MM 55 mg QD 55 fostamatinib 55 Patency 55 analgesic efficacy 55 dyskinesia PD LID 55 Dacogen injection 55 Clinicaltrials.gov 55 PICSO ® 55 RTOG 55 sirolimus eluting 55 multiple ascending dose 55 DCCT 55 CRESTOR #mg 55 Prostate Cancer Prevention 55 SPIRIT FIRST 55 phase 2a 55 unblinding 55 Study ADCS 55 epoetin alpha 55 randomized multicenter Phase III 55 RenalGuard System TM 55 DSMB 55 MabCampath 55 REVIVE Diabetes 55 brivaracetam 55 NCT# 55 International Verapamil SR 55 pegylated interferon alfa 2b 55 meta analyzes 55 ToGA 55 NCCTG N# 55 pertuzumab 55 safety tolerability pharmacokinetic 55 HeFT 55 clevidipine 55 ELCAP 55 Phase IIB 55 GEM OS1 55 PROactive Study 55 CYPHER ® Sirolimus eluting 55 Ovarian PLCO Cancer 55 Microplasmin 55 Phase 1b dose escalation 55 Multicenter Automatic Defibrillator Implantation 55 Tracleer R 55 observational studies 55 VICTOR E1 55 galiximab 55 fistulizing Crohn disease 55 rt PA 55 ADAGIO study 55 phase IIb III 55 Sirolimus eluting Coronary Stent 55 carotid artery stenting CAS 55 Cimzia ® certolizumab pegol 55 everolimus eluting stents 55 oral anticoagulation 55 CYPHER ® Stent 55 pharmacodynamics 55 Controlled Trial 55 Tolvaptan 55 PCI ExTRACT TIMI 55 Endarterectomy 55 NCCTG 55 FDA Investigational Device 55 ACTEMRA TM 55 Rosuvastatin 55 ERATO 55 Current Controlled Trials 55 tolvaptan 55 FIRAZYR 55 EXPLORE Xa 55 ACTEMRA 55 RE MODEL 55 paclitaxel eluting stents 55 Liraglutide Effect 55 IMPACT IMmunotherapy 55 Edwards SAPIEN valve 55 lorcaserin Phase 55 Betaferon R 55 GELA 55 Phase IIA 55 evaluating Vectibix 55 Degarelix 55 sirolimus eluting stents 55 HIVNET 55 sirolimus eluting stent 55 MERLIN TIMI 55 unstable angina UA 55 CYPHER R stent 55 interferon gamma 1b 55 EMPHASIS HF trial 55 Pre RELAX AHF 55 Glucosamine Chondroitin Arthritis 55 Phase 2a 55 recurrent glioblastoma multiforme 55 MIVI TRUST 55 bioequivalency 55 lanthanum carbonate 55 HuMax EGFr 55 ANRS 55 XIENCE V Everolimus Eluting 55 COSIRA trial 55 ALSYMPCA 55 Proellex TM 54 sunitinib 54 coronary intervention 54 patients undergoing CABG 54 cilostazol 54 NEVO 54 demonstrated clinically meaningful 54 atherothrombotic disease 54 Initiate Phase 54 Unstable Angina 54 IMPACT DCM 54 Raptiva r 54 IMPROVE IT 54 Prospective Multicenter 54 assessing T DM1 54 adalimumab 54 SUCCEED trial 54 Phase Ib clinical trials 54 intermittent dosing 54 trastuzumab emtansine T DM1 54 Glatiramer Acetate 54 darunavir ritonavir 54 BETAS 54 Placebo Controlled 54 CYPHER R Sirolimus eluting 54 undergoing elective percutaneous 54 CHOP chemotherapy 54 Phase III AFFIRM 54 Epirubicin 54 #mg dosing 54 acyclovir Lauriad R 54 Pivotal Study 54 ID NCT# 54 ATTAIN 54 eprotirome 54 Vertos II 54 non valvular atrial 54 GAMMAGARD 54 bendamustine 54 TEMSO 54 CINQUIL 54 ELACYT 54 INTERCEPT platelets 54 Evaluation WISE 54 Randomized Double blind 54 dosing regimens 54 adult chronic ITP 54 MGd 54 Oral Fingolimod 54 evaluating Actimmune 54 ENDEAVOR III 54 tanespimycin 54 Percutaneous Coronary Intervention 54 Atherosclerosis MESA 54 Blind Placebo Controlled 54 Asthma Intervention 54 Arimidex Tamoxifen Alone 54 ILLUSTRATE 54 randomized controlled trials RCTs 54 DIRECT Trial 54 OPT CHF 54 composite endpoint 54 superficial bladder cancer 54 TMC# r 54 REFLEX 54 Digital Mammographic Imaging 54 ZYBRESTAT fosbretabulin 54 National Surgical Adjuvant 54 PARTNER Trial 54 Group B CALGB 54 Randomized Placebo Controlled 54 PEG IFN 54 REMEDIAL II 54 EMPHASIS HF 54 IIa trial 54 tolerability pharmacokinetics 54 ANCHOR trial 54 Infarct 54 CONQUER OB 54 ONTARGET R 54 CORD II 54 NSTE ACS 54 ticagrelor 54 prospective observational studies 54 lacosamide 54 IN.PACT Falcon 54 RAPAFLO R 54 palonosetron 54 CALERIE 54 evaluable patients 54 OZURDEX ® 54 Vasogen Celacade 54 Scandinavian Simvastatin Survival 54 Multiethnic Study 54 vicriviroc 54 BoNTA 54 Sibutramine Cardiovascular Outcomes 54 IMPACT DCM clinical 54 TQT 54 COPAXONE R 54 dirucotide MBP# 54 REVLIMID lenalidomide 54 headache nasopharyngitis 54 ALLHAT 54 pharmacodynamic PD 54 Randomized Clinical Trial 54 carotid artery stenting 54 mg BID 54 concurrent chemoradiation 54 comparator arm 54 acute PAO 54 tocilizumab 54 Phase 1b clinical trials 54 LHRH receptor positive 54 Heart Failure Trial 54 dose cohorts 54 INTERHEART study 54 morphometric vertebral fractures 54 Multicenter Phase 54 strontium ranelate 54 Hepatocellular Carcinoma HCC 54 cathepsin K inhibitor 54 RIBBON 54 intravenous dosing 54 posaconazole 54 ANDROMEDA 54 HF ACTION 54 Subgroup analysis 54 PREVENT IV 54 complement inhibitor eculizumab 54 ACUITY trial 54 Ziprasidone 54 SCENESSE ® 54 Acute Coronary Syndromes ACS 54 boosted protease inhibitor 54 prespecified 54 RCTs 54 landmark ATHENA study 54 Xelox 54 Relieve Depression STAR 54 opioid induced bowel dysfunction 54 afatinib 54 transcatheter aortic valve implantation 54 pharmacodynamic profile 54 epidemiologic studies 54 retaspimycin 54 BCR ABL inhibitor 54 NATRECOR R 54 Metabolic Efficiency 54 dosing cohorts 54 TAXUS TM 54 eluting stent 54 evaluating tivozanib 54 AZILECT ® 53 radiographic outcomes 53 Tanespimycin 53 Adalimumab 53 mesalazine 53 ceftazidime 53 antiplatelet agent 53 canakinumab 53 ELONVA 53 Zenvia ™ 53 hemodialysis patients 53 League Against Rheumatism 53 PreCISe study 53 ATACAND 53 Clinical Outcomes Utilizing Revascularization 53 unstable angina pectoris 53 Dialysis Outcomes 53 pitavastatin 53 plus Copegus R 53 gadobutrol 53 II Clinical Trial 53 Phase III TRIST 53 SUTENT ® 53 peginterferon alfa 2b 53 ancrod 53 dose cohort 53 monotherapy 53 corifollitropin alfa 53 oral FTY# 53 relapsed refractory multiple myeloma 53 symptomatic VTE 53 PREDICTIVE 53 THAT ARE DIFFICULT TO 53 carotid endarterectomy CEA 53 liver resection 53 multicenter clinical trials 53 Fracture Intervention Trial 53 fondaparinux 53 Complications Trial 53 DU #b 53 Augment Injectable 53 Afatinib 53 ILLUMINATE 53 retrospective observational 53 oral ridaforolimus 53 VESTASYNC 53 duplex ultrasonography 53 Genetics Consortium 53 Taxus Stent 53 invasive candidiasis 53 XIENCE TM 53 REGARDS 53 Phase III confirmatory 53 FOSRENOL R 53 novel VDA molecule 53 EQUIP OB 53 GIK infusion 53 NSABP C 53 FORTIS M 53 eszopiclone 53 SORT OUT 53 peptic ulcer bleeding 53 evaluating carfilzomib 53 retrospectively analyzed 53 pharmacokinetic studies 53 PROACT 53 HALTS 53 RE SURGE 53 TIMI 53 Resolute DES 53 Oral Insulin Capsule 53 CALGB # [001] 53 dyslipidaemia 53 REMINYL ® 53 inhibitor RG# 53 Ambulatory Blood Pressure 53 Cochrane Systematic Review 53 stage IIIB 53 Stent Restenosis 53 migraine prophylaxis 53 registrational trial 53 TEC #OL 53 Multicenter Randomized 53 stage IIIb IV 53 TM Drug Eluting 53 Sipuleucel T 53 AERAS-#/Crucell Ad# 53 ARIXTRA 53 Deforolimus 53 UPLIFT 53 DASISION 53 ACTOS ® 53 ofatumumab HuMax CD# 53 multicenter dose escalation 53 Nutrition EPIC 53 Immune Tolerance Network 53 Health Initiative WHI 53 GISSI 53 SEROQUEL 53 ClinicalTrials.gov 53 dosing cohort 53 Study Evaluating 53 alvimopan 53 NCIC CTG 53 prospectively stratified 53 Cancer Prevention ATBC 53 PREZISTA r 53 LPV r 53 Dapagliflozin 53 Drug Eluting Stent System 53 Diabetic Macular Edema DME 53 ECTRIMS 53 Pivotal Phase 53 Yondelis ® 53 PROMACTA 53 Phase IIb kidney transplant 53 SCD HeFT 53 CML CP 53 eplerenone 53 StemEx R 53 STEP BD 53 Phase III Pivotal 53 genotypic resistance 53 platelet inhibitor 53 antiretroviral naïve 53 daily Infergen 53 crizotinib PF # 53 histologically confirmed 53 bosentan 53 LibiGel Phase III 53 CCX# B 53 AIDS Clinical Trials 53 viral kinetics 53 HOPE TOO 53 mg/m2 dose 53 FOLOTYN ® 53 CIMZIA TM 53 tolerated dose MTD 53 Cloretazine 53 ICON7 53 EOquin TM 53 YONDELIS 53 ENDEAVOR IV clinical 53 ocular hypertension 53 Parkinson disease levodopa induced 53 fully bioabsorbable 53 miconazole Lauriad ® 53 antiarrhythmic drug 53 CONQUER 53 randomisation 53 CombAT 53 rosuvastatin #mg 53 Multicenter Randomized Double 53 MMX mesalamine 53 Phase #b/#a clinical 53 Navelbine 53 n = 53 Phase #b/#a trial 53 nulliparous women 53 budesonide foam 53 relapsed myeloma 53 tirofiban 53 CIMZIA ™ 53 CONSERV 53 Stenting Trial 53 Randomised Study 53 GFT# 53 JAK inhibitor 53 thromboprophylaxis 53 ABSSSI 53 acute HAE attacks 53 intravitreal insert 53 ACOMPLIA R 53 study1 53 SYNTAX trial 53 PROMUS Element Stent 53 refractory metastatic colorectal cancer 53 PROTECT AF 53 satraplatin Phase 53 Vimpat ® lacosamide 53 de novo kidney transplant 53 Paediatric Endocrinology 53 dose placebo controlled 52 CHAMPION PLATFORM 52 Phase 2b Study 52 transfemoral 52 REYATAZ r 52 postmenopausal osteoporotic women 52 sitaxsentan 52 ezetimibe simvastatin 52 Neulasta R 52 retrospectively reviewed 52 Combination REOLYSIN R 52 meta regression 52 APTIVUS r 52 TORISEL 52 Phase III HEAT 52 BLOSSOM 52 Diabetologia 52 Cohort 52 J Clin Oncol 52 neratinib 52 COMPARE 52 fluvastatin 52 Cloretazine ® 52 telmisartan 52 PHASE III 52 Safinamide 52 Carotid Endarterectomy 52 telaprevir dosing 52 Echocardiographic 52 INSPIRE Trial Phase III 52 Clinical Evaluation 52 SYMMETRY trial 52 tiotropium 52 candesartan cilexetil 52 VFEND 52 CYPHER R Stent 52 Neovascular AMD 52 papillary renal cell carcinoma 52 Neoadjuvant 52 sorafenib Nexavar 52 Primary endpoints 52 WHIMS 52 intraobserver 52 INFORM 52 cellulose sulfate 52 Angiographic 52 ORAL Sync 52 Dose escalation 52 ug dose 52 Traficet EN 52 Coronary Artery Bypass Graft 52 Subgroup Analysis 52 DEFER 52 genotype 1a 52 Bowel Project NSABP 52 investigational antiplatelet agent 52 reslizumab 52 AZILECT R 52 BEACOPP 52 PFO closure 52 MEND CABG II 52 refractory CLL 52 XIENCE V PROMUS Stent

Back to home page